Author Archives: Inês Martins PhD

Study: PRX-102 Is Safe, Slows Kidney Disease in Fabry Patients Previously Taking Replagal

One-year treatment with Protalix BioTherapeutics‘ investigational enzyme replacement therapy PRX-102 (pegunigalsidase alfa) is safe, well-tolerated and appears to more effectively slow kidney disease progression in Fabry disease patients previously treated with Replagal (agalsidase alpha), results from a Phase 3 clinical trial suggest. Patients also experienced…